1Marmont A, Frassoni F, Bacigalupo A, et al. Recurrence of Ph-positive leukemia in donor cells after marrow transplantation for chronic granulocvtic leukemia. N Engl J Med, 1984,310:903-906.
2Elmaagacli AH, Beelen DW, Schaefer UW. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transolantation. Bone Marrow Transplant, 1997,20 : 1045-1055.
3Prinz E, Keil F, Kalhs P, et al. Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation. Ann Hematol,2003 ,82 :295-298.
4Nordlander A, Mattsson J, Ringden O, et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant ,2004,10 : 195-203.
5Choi SJ ,Lee J-H ,Lee JH ,et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion:a high incidence of isolated extramedullary relapse. Leukemia,2004,18 : 1789-1797.
6Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.Cancer Control,2002,9:123-137.
7Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood,2000,95:67-71.
8Leis J, Porter DL. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation. Leuk Lymphoma,2002,43:9-17.
9Porter DL, Collins RH Jr, Hardy C, et al. Treatment of replased leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood ,2000,95 : 1214-1221.
10Peggs K, Kottaridis PD,Morris ME, et al. Escalating dose donor lymphocyte infusions following non-myeloablative allogeneic transplantation are associated with minimal toxicity with sibling donors but significant risk of severe GVHD with unrelated donors. Blood ,2001,98:672a.
2Lembuis.T,Wellss,Seheffold,et al.Autologous cytokine-induced killer cells for treatment of rllapsed Hodgkin s disease and non-Hodgkin's lymphoma.Blood,2000;96:839a.
3Elmmaagacli AH,Beelem DW,et al.A retrospective single centre study of the outcome of five different after allogeneic bone marrow transplation.BMT,1997;20:1045-1055.
4Schmid C,Labopin M,Nagler A,et al:Donor lymphocyte infusion in The treatment of first hematological relapse after allogeneic stem cell Transplantation in adults with acute myeloid leukrnia:A retrospective Risk factors analysis and comparison with other strategies by the EBMT leukemia working party.J.Clinical Oncol,2007:25(31):4939-4945.
5SakaiM,ohashi.K,et al.Cytogenetic abnormalities without evidence of relapse after treatment with imatimib and stem cell transplantion in a patient with Ph-postive All.Int.J.Hematol,2005;81:171-173.
6Agis H,Mannhalter C,Sperr WR,et al.Detection of trisomy 8 in donor ph+ cells in a patient with ph+ chronic myeloid leukemia in successfully treated with Imatimib in relapse after allogeneic transplantation.Leuk Lymphoma,2004;45:1453-1458.
7Yoshimitsum M,Fujiwara H,Ozaki A,et al.Case of a patient with phiadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloabative allogeneic hematopoietic srem cell transplantion treated successfully with imatinib and sequential donoe lymphocyte infusions.Int.J.Hematol,2008;88:331-335.
